ArticleAging and disease2025
Global Burden of Chronic Obstructive Pulmonary Disease and Heart Failure Comorbidity in Older Adults: An Analysis of the Global Burden of Disease Study.
Article in Aging and disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Global, Regional, and National Burden of Heart Failure Attributable to Chronic Obstructive Pulmonary Disease From 1990 to 2021, With Projections to 2050.Journal of preventive medicine and public health = Yebang Uihakhoe chi · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Heart failure (HF) is a common comorbidity for older patients of chronic obstructive pulmonary disease (COPD). This study aimed to investigate the global burden of COPD-HF comorbidity among older adults from 1990 to 2021 and make a prediction till 2050. Data on prevalence and years lived with disability (YLDs) for COPD-HF comorbidity among older adults aged 60 or above were obtained from the Global Burden of Diseases Study 2021. Absolute number and age-standardized rate (ASR) per 100,000 individuals were used to compare the disease burden by sex, age, severity and region. Temporal trends in ASR from 1990 to 2021 were analyzed using Joinpoint models, while Bayesian age-period-cohort models were introduced to project ASR till 2050. From 1990 to 2021, global prevalent cases and YLDs of COPD-HF comorbidity among older adults increased, and ASRs also exhibited a sustained increase. The disease burden will continue to rise till 2050. Moreover, the comorbidity burden was higher in males than females, and increased with age. Additionally, severe and treated cases were the predominant subtypes of this comorbidity. Low and middle socio-demographic index (SDI) regions tended to bear higher disease burden. The global burden of COPD-HF comorbidity was substantially heavy with a consistent rising trend from 1990 to 2021 in older adults. The disease burden will rise till 2050. Disparities of the disease burden existed in sex, SDI, and geographic region worldwide. This study has implications for re-allocating resources to early identification and effective treatment of COPD, HF, and COPD-HF comorbidity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.